(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
3 days till quarter result
(amc 2024-05-07)
Expected move: +/- 6.15%
0.79% $ 20.35
@ $25.39
Wydano: 14 vas. 2024 @ 22:49
Zwrot: -19.85%
Poprzedni sygnał: vas. 14 - 16:30
Poprzedni sygnał:
Zwrot: 3.63 %
Live Chart Being Loaded With Signals
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis...
Stats | |
---|---|
Dzisiejszy wolumen | 444 362 |
Średni wolumen | 689 075 |
Kapitalizacja rynkowa | 1.53B |
EPS | $0 ( 2024-05-02 ) |
Następna data zysków | ( $-0.190 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -19.95 |
ATR14 | $0.0110 (0.05%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Eastham Karin | Buy | 10 000 | Common Stock |
2024-04-01 | Eastham Karin | Sell | 10 000 | Common Stock |
2024-04-01 | Eastham Karin | Sell | 10 000 | Stock Option (right to buy) |
2024-03-15 | Chambers Rebecca | Buy | 4 318 | Common Stock |
2024-03-15 | Chambers Rebecca | Sell | 2 189 | Common Stock |
INSIDER POWER |
---|
32.67 |
Last 99 transactions |
Buy: 1 146 076 | Sell: 688 515 |
Wolumen Korelacja
Veracyte Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
SPTN | 0.949 |
VORB | 0.945 |
SSTI | 0.943 |
AKAN | 0.941 |
APPS | 0.94 |
MMAC | 0.939 |
AGRX | 0.938 |
PEAR | 0.938 |
BNRG | 0.937 |
LPSN | 0.937 |
10 Najbardziej negatywne korelacje | |
---|---|
GXII | -0.965 |
TBSAU | -0.958 |
AGGR | -0.958 |
RMRM | -0.957 |
HERA | -0.955 |
SCOB | -0.953 |
LGAC | -0.953 |
NVSA | -0.953 |
AEAC | -0.953 |
CRZN | -0.952 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Veracyte Inc Korelacja - Waluta/Towar
Veracyte Inc Finanse
Annual | 2023 |
Przychody: | $361.05M |
Zysk brutto: | $223.15M (61.81 %) |
EPS: | $-1.020 |
FY | 2023 |
Przychody: | $361.05M |
Zysk brutto: | $223.15M (61.81 %) |
EPS: | $-1.020 |
FY | 2022 |
Przychody: | $296.54M |
Zysk brutto: | $194.95M (65.74 %) |
EPS: | $-0.510 |
FY | 2021 |
Przychody: | $219.51M |
Zysk brutto: | $145.11M (66.11 %) |
EPS: | $-1.419 |
Financial Reports:
No articles found.
Veracyte Inc
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej